Interim Report January - September 2002

Report this content

BIOINVENT INTERIM REPORT 1 JANUARY - 30 SEPTEMBER 2002 q BioInvent is developing an antibody-based drug against HIV based on target structures acquired from a US biotech company. q q Net revenue for January-September 2002 increased to SEK 65.3 million (44.7). q q Cash flow from current operations and investment activity, January-September 2002 amounted to SEK-14.7 million (-53.4). Liquid funds at end of period: SEK 376.0 million (360.0). q Loss after net financial items for January-September 2002: SEK-29.8 million (-25.7). Contact: Any questions regarding this report will be answered by: Svein Mathisen, President and CEO, +46 (0)46 286 85 67 or Jonas Källmén, CFO, +46 (0)46 286 38 12. The report is also available at: www.bioinvent.com BioInvent International AB (publ.) Co. reg. no. 556537-7263 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00590/wkr0002.doc The full report http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00590/wkr0003.pdf The full report

Subscribe

Documents & Links